We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Evelo develops and sells electric bicycles using a direct-to-consumer distribution...
Evelo develops and sells electric bicycles usin...
Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innovivaâs portf...
Innoviva, Inc. (NASDAQ: INVA) is focused on roy...
Natera is a rapidly-growing diagnostics company with proprietary bioinformatics an...
Natera is a rapidly-growing diagnostics company...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Eidos is a clinical stage biopharmaceutical company focused on addressing the larg...
Eidos is a clinical stage biopharmaceutical com...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.